There’s definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money. Ginkgo Bioworks (NYSE:DNA) is certainly an interesting company and Ginkgo Bioworks stock is beaten down, but the risk-to-reward profile just isn’t favorable right now.Ginkgo Bioworks, which specializes in cell programming and biosecurity, has a promising arrangement with a giant in the global biotechnology market. This cannot be overlooked, and we’ll discuss the details in a mome ...